Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL744346 | 0.87 | DPP4 (0.42) | DPP4DPP7DPP8DPP9CYP3A4 | |
| SCHEMBL743044 | 0.87 | DPP4 (0.42) | DPP4DPP7DPP8DPP9CYP3A4 | |
| SCHEMBL16750215 | 0.87 | DPP4 (0.42) | DPP4DPP7DPP8DPP9CYP3A4 | |
| SCHEMBL22950650 | 0.84 | DPP4 (0.46) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL22950652 | 0.84 | DPP4 (0.46) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL13005310 | 0.84 | DPP4 (0.46) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL19544604 | 0.79 | TAAR1 (0.41) | DPP4DPP7DPP8DPP9CYP3A4 | |
| SCHEMBL22086028 | 0.78 | PIN1 (0.45) | DPP4DPP7 | |
| SCHEMBL15166515 | 0.78 | DPP4 (0.49) | DPP4DPP7DPP8CYP3A4 | |
| SCHEMBL12187618 | 0.78 | DPP4 (0.39) | DPP4DPP7DPP8DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086765-A1 | NOVEL INTERMEDIATES FOR PREPARING DPP-IV INHIBITORS, PREPARING METHOD THEREOF AND PREPARING METHOD OF DPP-IV INHIBITORS USING THE SAME | KYUNG DONG PHARM. CO., LTD. (KR) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086765-A1 | NOVEL INTERMEDIATES FOR PREPARING DPP-IV INHIBITORS, PREPARING METHOD THEREOF AND PREPARING METHOD OF DPP-IV INHIBITORS USING THE SAME | DPP4, DPP7, DPP9 | DPP4 1/4885DPP7 2/4885DPP8 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.